Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

HIV vaccine 'could be on the market in five years'

Science Editor,Steve Connor
Tuesday 09 July 2002 00:00 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

A vaccine against Aids could be available within five years if it is shown to prevent HIV infection in at least a third of the people taking part in two clinical trials due to end next year, an American biotechnology company said yesterday.

Vaxgen, which is based in California, is the only company testing a potential Aids vaccine in phase-three clinical trials – the final stage before drugs are approved for wider use – and will analyse the results in 2003 to see if the vaccine actually prevents HIV infection.

Yesterday, at the international Aids conference in Barcelona, Vaxgen said early indications showed that most of the nearly 8,000 volunteers in the two trials taking place in the US and Thailand are producing the necessary antibodies that may prevent HIV from attacking the body.

The crucial question, however, is whether the vaccine has any impact on levels of infection in the groups taking the treatment compared to unvaccinated people.

Donald Francis, the head of Vaxgen, said that the vaccine has already been shown to prevent HIV infection in chimpanzees and he was optimistic that it could now also be shown to work on humans.

"I think we will get protection [from the virus], but I don't know what level we'll get. If all goes well, [the vaccine] could be available by the end of 2004 or early 2005," Dr Francis said.

Vaxgen's vaccine is based on a genetically engineered HIV protein, called gp120, which the virus uses to break into a human cell where it takes over the genetic machinery to make copies of itself.

Two earlier clinical trials found that the vaccine was safe and that it appeared to stimulate the immune system to make protective antibodies. However, they failed to establish whether the vaccine has any overall effect on protecting people against HIV infection.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in